Researchers find that a lipid damage signal both activates and limits the complement system during cell death, helping ...

Advancing a neuromuscular franchise with claseprubart, a highly potent, investigational classical pathway inhibitor, with best-in-disease ...

Researchers model how shared qubits interfere in quantum computing, generalizing the Owicki–Gries method to account for ...

Annexon (NASDAQ:ANNX) said it expects to report the month-15 primary-endpoint analysis from its Phase III ARCHER II trial of vonaprument in geographic atrophy, or GA, during the fourth quarter of 2026 ...

Annexon's stock hinges on the Q4 2026 readout of its Phase 3 ARCHER II trial's month-15 primary endpoint in geographic ...

Ali Habib, MD, a neuromuscular specialist at UCI Health, breaks down the phase 3 NIMBLE trial's patient population, four ...

Can entangled masses ever overcome inherent limitations to detect gravitational interactions? Simulations reveal protocols ...

In pharmaceutical research, quantum computers could serve as specialized instruments, tackling complex molecular simulations ...

A new review maps how a clonal B-cell disorder and complement-driven hemolysis define cold agglutinin disease, why steroids ...

Hematology research now needs new evidence strategies as targeted therapies create smaller, more specialized patient groups ...

BRISBANE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at ...

Annexon (ANNX) news covers C1q-targeted immunotherapy programs, vonaprument in geographic atrophy, tanruprubart in GBS, results and equity grants.